Arbutus Biopharma

Ivexsol Announces The Appointment Of Amitabha Deb, Ph.D.

Retrieved on: 
Tuesday, January 4, 2022
Multimedia, CSO, Arbutus Biopharma, Malignant transformation, Research, Cleveland Clinic, Virus, Senior, Intelligence, Management, Vaccine

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.

Key Points: 
  • LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.
  • Amitabha Deb, Ph.D. has 30 years of successful experience in the Biopharma industry.
  • As Senior Vice President of Process Sciences and MS&T at iVexSol, Amitabha will lead the efforts to develop closed system, automated processes for lentiviral production and purification using iVexSol's proprietary stable cell lines.
  • iVexSol, Inc. is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made.

Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

Retrieved on: 
Tuesday, December 7, 2021
Research, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, U.S. Securities and Exchange Commission, NYSE, NASH, CANF, Company, Erectile dysfunction, Writing, Liver cancer, Colon, Forward-looking statement, SEC, Patient, Technology, HCC, Hepatocellular carcinoma, Fatty liver disease, Therapeutic index, Drug development, PASI, Data analysis, Food, Liver, Cancer, Industry, Arbutus Biopharma, Psoriasis, Prostate, Inflammation, TASE, Melanoma, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Institute of Liver and Biliary Sciences, Pharmaceutical industry

The 16-week treatment period is the primary endpoint of the study, and the Company expects to announce topline results during Q1 2022.

Key Points: 
  • The 16-week treatment period is the primary endpoint of the study, and the Company expects to announce topline results during Q1 2022.
  • The randomized, double blind, active and placebo controlled study is being conducted in Europe, Israel, and Canada.
  • Completion of treatment in a Phase III study is a significant milestone for our lead drug candidate.
  • We were encouraged by the positive interim data analysis provided by the Independent Data Monitoring Committee following treatment of the first 200 patients in this study.

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

Retrieved on: 
Wednesday, November 24, 2021
Patient, Private Securities Litigation Reform Act, End-user license agreement, CEO, Licensed production, US Foods, Annual report, Company, Arbutus Biopharma, Achievement, Tongue, Lists of diseases, Post-traumatic stress disorder, Plasma, PTSD, Group, Ketamine, Central nervous system, IV, Therapy, Nature, COVID-19, Psychiatry, U.S. Securities and Exchange Commission, CRPS, Nasdaq, Complex regional pain syndrome, License, FDA, Movement disorders, Drug development, CNS, Degenerative disease, Food, Catalist, Pharmaceutical industry, Risk management, Online shopping

The US Food and Drug Administration (FDA) has granted Wafermine Orphan Drug designation for the treatment of CRPS.

Key Points: 
  • The US Food and Drug Administration (FDA) has granted Wafermine Orphan Drug designation for the treatment of CRPS.
  • Our team is very excited to be developing both acute, in SLS-002, and a potentially chronic, in SLS-003, ketamine-based therapy programs.
  • "We are delighted to collaborate with Seelos Therapeutics, whose deep insights in ketamine drug development make them an ideal partner to further the development of Wafermine and the other sublingual ketamine products," said Eddy Lee, Chairman and CEO of iX Biopharma.
  • We are therefore excited that this commercially significant agreement with Seelos is a validation of our ability to deliver on this strategy."

Strategic Relationship Between SCIEX and RedShiftBio® Expands the Reach of Disruptive Technology to Address Challenges With Rapid Secondary Structure Assessment of Biotherapeutics

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Health, Science, Other Science, Pharmaceutical, Health, Molecule, Safety, Biomarker, MMS, General manager, IR, Disease, Technology, CE, Multimedia, Arbutus Biopharma, Mass spectrometry, Microfluidic modulation spectroscopy, LC-MS, Protein, Organic acid, Research, Solution, Drug development, Fine chemical, Pharmaceutical industry, SCIEX, RedShift, SCIEX, REDSHIFT

This agreement will enable SCIEX to resell the AQS3pro from RedShiftBio throughout the United States, alongside its market-leading CE and LC-MS solutions.

Key Points: 
  • This agreement will enable SCIEX to resell the AQS3pro from RedShiftBio throughout the United States, alongside its market-leading CE and LC-MS solutions.
  • View the full release here: https://www.businesswire.com/news/home/20211116005951/en/
    The AQS3pros novel MMS technology allows users fast, ultra-sensitive, and accurate analysis of biomolecules higher order structure.
  • I am thrilled that RedShiftBio has found such a strong partner in SCIEX.
  • Their continuous drive for innovation and commercial reach into the biopharmaceutical development segment will further accelerate access to MMS technology.

Former Novartis Executive Dr. Marie Lindner Joins Orthogon Therapeutics’ Board of Directors

Retrieved on: 
Monday, November 15, 2021
Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, Biocuration, BK, Therapy, Novartis, Arbutus Biopharma, Infection, Growth, Shire (pharmaceutical company), BK virus, Strategic partnership, Company, Ness Ziona, Drug discovery, Pharma, Internal medicine, Patient, Drug development, Pharmaceutical industry

Orthogon Therapeutics LLC, a drug development company focused on designing innovative antivirals and anti-infective therapeutics, announced that it has appointed Dr. Marie Lindner as an independent director to its board of directors.

Key Points: 
  • Orthogon Therapeutics LLC, a drug development company focused on designing innovative antivirals and anti-infective therapeutics, announced that it has appointed Dr. Marie Lindner as an independent director to its board of directors.
  • Prior to a BioPharma career that spanned over 30 years, Dr. Marie Lindner was board certified in internal medicine and clinical nutrition.
  • Her extensive background in biotech and with global pharmaceutical firms sets to strengthen the Orthogon board of directors.
  • Orthogon Therapeutics is a privately held drug discovery and development company developing a portfolio of infectious disease assets, including antiviral therapeutics.

Exyte with Record Order Intake in 9M/2021

Retrieved on: 
Thursday, November 11, 2021
Industry, Engineering, EMEA, List of life sciences, Arbutus Biopharma, DTC, Semiconductor, Biotechnology, YOY, EBIT, History, EUR, Time, Data, BLS, ATF, CFO, Lithium

STUTTGART, Germany, Nov. 11, 2021 /PRNewswire/ --Exyte continued its excellent performance during the first nine months of 2021, reaching a record order intake of 5,132 million (9M/2020: 3,184 million) thanks to a strong demand in the APAC and EMEA regions.

Key Points: 
  • STUTTGART, Germany, Nov. 11, 2021 /PRNewswire/ --Exyte continued its excellent performance during the first nine months of 2021, reaching a record order intake of 5,132 million (9M/2020: 3,184 million) thanks to a strong demand in the APAC and EMEA regions.
  • Due to a high demand in all regions, sales increased by 21.3% to 3,395 million (9M/2020: 2,800 million).
  • With new significant projects awarded in Israel, the business segment Data Centers (DTC) reached an order intake of 175 million (9M/2020: 98 million).
  • In 2020, Exyte generated sales of EUR 4.1 billion with around 4,900 highly experienced and motivated employees.

Exyte with Record Order Intake in 9M/2021

Retrieved on: 
Thursday, November 11, 2021
Industry, Engineering, EMEA, List of life sciences, Arbutus Biopharma, DTC, Semiconductor, Biotechnology, YOY, EBIT, History, EUR, Time, Data, BLS, ATF, CFO, Lithium

STUTTGART, Germany, Nov. 11, 2021 /PRNewswire/ -- Exyte continued its excellent performance during the first nine months of 2021, reaching a record order intake of  €5,132 million (9M/2020: €3,184 million) thanks to a strong demand in the APAC and EMEA regions. Sales increased by 21.3% to €3,395 million with adjusted EBIT reaching €178 million. Advanced Technology Facilities (ATF) remained the largest business segment and the region EMEA the strongest region for the time being.

Key Points: 
  • STUTTGART, Germany, Nov. 11, 2021 /PRNewswire/ --Exyte continued its excellent performance during the first nine months of 2021, reaching a record order intake of 5,132 million (9M/2020: 3,184 million) thanks to a strong demand in the APAC and EMEA regions.
  • Due to a high demand in all regions, sales increased by 21.3% to 3,395 million (9M/2020: 2,800 million).
  • With new significant projects awarded in Israel, the business segment Data Centers (DTC) reached an order intake of 175 million (9M/2020: 98 million).
  • In 2020, Exyte generated sales of EUR 4.1 billion with around 4,900 highly experienced and motivated employees.

CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

Retrieved on: 
Tuesday, November 9, 2021
Commercial Building & Real Estate, Construction & Property, Other Health, Pharmaceutical, Oncology, Managed Care, General Health, Hospitals, Science, Biotechnology, Other Science, Nursing, Health, Other Construction & Property, Research, Centurion, Neurodegeneration, ImmunityBio, Las Vegas Global Economic Alliance, Cancer, Neoplasm, Security (finance), Disease, Niemann–Pick disease, Arbutus Biopharma, Technology, Medical tourism, Gaucher's disease, Research, Multimedia, NPC, Annual report, CytRx, Therapy, U.S. Securities and Exchange Commission, Controlled internal drug release, Toxicity, OTCQB, Biology, Patient, Letter, Pharmaceutical industry, Casino

View the full release here: https://www.businesswire.com/news/home/20211109005642/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211109005642/en/
    Rendered images of proposed Centurion BioPharma center.
  • The Las Vegas Global Economic Alliance has issued a letter of support for the project ahead of the planned luncheon.
  • "After approximately two years of planning and discussions, we are excited to have the opportunity to present our plans to construct a much-needed state-of-the-art cancer treatment center in Las Vegas, Nevada.
  • We also believe the center could become a major hub for medical tourism and scientific development in Nevada.

POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

Retrieved on: 
Thursday, September 23, 2021
Pharmacokinetics, Achievement, Patient, Radionuclide, Private Securities Litigation Reform Act, NASDAQ, Intention, Cancer, SPLASH, Physician, Prostate cancer, Toxicity, Terminology, ORR, Risk, RPF, COVID-19, Actinium-225, Arbutus Biopharma, Forward-looking statement, Safety, SEC, GLOBE, Pharmaceutical industry, Medical imaging

INDIANAPOLIS, Indiana, Sept. 23, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced that the dosimetry and safety run-in of its Phase 3 SPLASH study evaluating PNT2002 for Metastatic Castrate Resistant Prostate Cancer (mCRPC) met all pre-specified criteria allowing for initiation of the randomization phase without changes to the study design.

Key Points: 
  • I would like to thank our team and partners for enabling the SPLASH trials randomization to begin ahead of schedule, said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma.
  • Our team and partners have done an amazing job of overcoming these difficulties, enabling the achievement of this SPLASH trial milestone.
  • The randomization phase of the study is expected to enroll approximately 400 patients across North America, Europe and the UK.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com.

IDEA Pharma and Protodigm Expand and Strengthen Team with Accomplished Industry Experts

Retrieved on: 
Friday, September 17, 2021
Thought, Virginia, Drawing, LinkedIn, Wharton, Magic, Fortune, Twitter, Mukherjee, CEO, Medicine, Virginia Commonwealth University, Knowledge, IDEA, Creativity, MBA, Research, Drug development, Arbutus Biopharma, Pharma, Industry, Fine chemical, Management

Sy Mukherjee comes from a pharma industry writing background, having worked at Fortune & Biopharma Dive previously, with a bachelor's degree from Dartmouth.

Key Points: 
  • Sy Mukherjee comes from a pharma industry writing background, having worked at Fortune & Biopharma Dive previously, with a bachelor's degree from Dartmouth.
  • Mukherjee will be instrumental to assisting IDEA Pharma and Protodigm CEO, Mike Rea, launch special projects.
  • "I am looking forward to working with Mike and the teams at IDEA and Protodigm, and help communicate this breakthrough thinking," said Mukherjee, Communications Architect, IDEA Pharma.
  • I am excited to immerse myself in this process of new age biotech transformation," said Dr. Lee, Medical Strategist, IDEA Pharma.